Asia Pacific Cancer Immunotherapy Market Size, Share, and COVID-19 Impact Analysis, By Product (Monoclonal Antibodies, Immunomodulators, and Oncolytic Viral Therapies & Cancer Vaccines), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, and Others), and Asia Pacific Cancer Immunotherapy Market Insights, Industry Trend, Forecasts to 2035

Asia Pacific Cancer Immunotherapy Market Insights Forecasts to 2035

• The Asia Pacific Cancer Immunotherapy Market Size was estimated at USD 129.5 Billion in 2024
• The Market Size is Expected to Grow at a CAGR of around 12.16% from 2025 to 2035
• The Asia Pacific Cancer Immunotherapy Market Size is Expected to Reach USD 457.5 Billion by 2035

The Asia Pacific Cancer Immunotherapy Market is anticipated to reach USD 457.5 billion by 2035, growing at a CAGR of 12.16% from 2025 to 2035. The growing prevalence of cancer, demand for innovative & effective treatment options, and investment in oncology research are driving the cancer immunotherapy market in the Asia Pacific region.  

Market Overview

The Asia Pacific cancer immunotherapy market refers to the market emphasizing development and providing treatments that harness the body’s immune system to fight cancer. Cancer immunotherapy is a type of cancer treatment that powers the body’s immune system to fight cancer. It ultimately works by boosting or altering the immune system to recognize and attack cancer cells. The growing burden of disease and the approval of novel immunotherapies are responsible for driving the cancer immunotherapy market. Further, there is growing emphasis on specific molecules involved in cancer growth that minimize the damage to healthy cells. For instance, advancements in CAR-T cell therapy showcase the potential for genetically engineered immune cells to specifically target cancer cells.

Report Coverage

This research report categorizes the market for the Asia Pacific cancer immunotherapy market based on various segments and regions and forecasts revenue growth and analyzes trends in each submarket. The report analyses the key growth drivers, opportunities, and challenges influencing the Asia Pacific cancer immunotherapy market. Recent market developments and competitive strategies such as expansion, product launch, and development, partnership, merger, and acquisition have been included to draw the competitive landscape in the market. The report strategically identifies and profiles the key market players and analyses their core competencies in each sub-segment of the Asia Pacific cancer immunotherapy market.

Driving Factors

The growing prevalence of cancer is anticipated to drive the market demand for cancer immunotherapy. For instance, it was estimated that cancer incidence in Asia was 169.1 per 100000, accounting for 49.3% of global cancer incidence. The emergence of an innovative approach to cancer immunotherapy, including CAR-T cell therapy contributing to propel the market growth. Further, increasing research and development in the field of oncology contributes to promoting the market growth.

Restraining Factors

The increased cost of cancer immunotherapy and demand for improved efficacy & accessibility are restraining the market. Further, the stringent regulatory approval process is challenging the market growth.

Market Segmentation

The Asia Pacific cancer immunotherapy market share is classified into product and application.

• The monoclonal antibodies segment held the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific cancer immunotherapy market is segmented by product into monoclonal antibodies, immunomodulators, and oncolytic viral therapies & cancer vaccines. Among these, the monoclonal antibodies segment held the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. Monoclonal antibodies are designed for targeting specific proteins on cancer cells, and enhance the immune system’s ability to recognize and destroy cancer cells.

• The lung cancer segment held the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period.

The Asia Pacific cancer immunotherapy market is segmented by application into lung cancer, breast cancer, colorectal cancer, melanoma, prostate cancer, and others. Among these, the lung cancer segment held the largest revenue share in 2024 and is expected to grow at a significant CAGR during the forecast period. The emergence of innovative drug treatment, including pembrolizumab for the treatment of non-small cell lung cancer, is driving the market growth in the lung cancer segment.

Competitive Analysis:

The report offers the appropriate analysis of the key organizations/companies involved within the Asia Pacific cancer immunotherapy market along with a comparative evaluation primarily based on their product offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.

List of Key Companies

• Amgen Inc.
• Bristol-Myers Squibb Company
• Eli Lilly and Company
• AstraZeneca Plc.
• GlaxoSmithKline Plc.
• Bayer AG
• F. Hoffmann-La Roche Ltd.
• Pfizer Inc. 
• Others

Recent Developments:

• In May 2022, Roche Pharma announced the India launch of PHESGO- the first ever fixed dose formulation in oncology to combine two monoclonal antibodies- Perjeta (pertuzumab) and Herceptin (trastuzumab) with hyaluronidase, administered by subcutaneous injection in combination with intravenous chemotherapy, for the treatment of early and metastatic HER2-positive breast cancer.

Key Target Audience

• Market Players
• Investors
• End-users
• Government Authorities 
• Consulting and Research Firm
• Venture capitalists
• Value-Added Resellers (VARs)

Market Segment

This study forecasts revenue at Asia Pacific, regional, and country levels from 2020 to 2035. Spherical Insights has segmented the Asia Pacific Cancer Immunotherapy Market based on the below-mentioned segments:

Asia Pacific Cancer Immunotherapy Market, By Product

• Monoclonal Antibodies
• Immunomodulators
• Oncolytic Viral Therapies & Cancer Vaccines

Asia Pacific Cancer Immunotherapy Market, By Application

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Melanoma
• Prostate Cancer
• Others